A PHASE 1 STUDY OF PALBOCICLIB (IND#141416) A CDK 4/6 INHIBITOR IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LYMPHOBLASTIC LYMPHOMA (LL)

Brief description of study

This study is evaluating safety and feasibility of palbociclib in combination with an established re-induction platform for children, adolescents and young adults with relapsed/refractory ALL and lymphoblastic lymphoma. Targeting cell cycle progression has been an effective therapeutic strategy in a spectrum of malignancies. Prior studies have shown that deregulation of the physiological cell cycle machinery is essential for both the induction and progression of ALL. Additionally, molecular targeting of the interaction of D type cyclins with cell cycle dependent kinases (CDK4 and 6) efficiently suppressed ALL growth and disease progression in vivo and this effect was augmented by concomitant delivery of cytotoxic agents.


Clinical Study Identifier: s19-00085
ClinicalTrials.gov Identifier: NCT03792256
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.